NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
16.86
+0.38 (2.31%)
At close: Nov 20, 2024, 4:00 PM
17.08
+0.22 (1.30%)
Pre-market: Nov 21, 2024, 7:41 AM EST
NovoCure Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 577.74 | 509.34 | 537.84 | 535.03 | 494.37 | 351.32 | Upgrade
|
Revenue Growth (YoY) | 14.63% | -5.30% | 0.53% | 8.23% | 40.72% | 41.62% | Upgrade
|
Cost of Revenue | 135.47 | 127.54 | 114.26 | 114.24 | 106.09 | 88.28 | Upgrade
|
Gross Profit | 442.26 | 381.8 | 423.58 | 420.79 | 388.27 | 263.04 | Upgrade
|
Selling, General & Admin | 382.06 | 386.97 | 306.41 | 263.18 | 225.45 | 184.62 | Upgrade
|
Research & Development | 210.4 | 220.99 | 206.09 | 201.3 | 132.01 | 79 | Upgrade
|
Operating Expenses | 592.46 | 607.96 | 512.5 | 464.49 | 357.46 | 263.63 | Upgrade
|
Operating Income | -150.19 | -226.16 | -88.91 | -43.69 | 30.81 | -0.59 | Upgrade
|
Interest Expense | -8.56 | -3.32 | -3.33 | -3.44 | -17.58 | -13.87 | Upgrade
|
Interest & Investment Income | 24.72 | 19.64 | 10.96 | 0.79 | 1.79 | 4.4 | Upgrade
|
Currency Exchange Gain (Loss) | 1.5 | -0.8 | -3.52 | -4.03 | 2.65 | -0.43 | Upgrade
|
Other Non Operating Income (Expenses) | -0.79 | -0.79 | -1.26 | -1.37 | -0.47 | -0.34 | Upgrade
|
EBT Excluding Unusual Items | -133.31 | -211.42 | -86.06 | -51.74 | 17.2 | -10.83 | Upgrade
|
Merger & Restructuring Charges | -8.23 | -6.23 | - | - | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | 26.4 | 26.4 | 4.83 | 0.31 | 1.32 | 2.33 | Upgrade
|
Asset Writedown | -0.48 | -0.48 | -0.61 | -0.64 | -0.41 | -0.33 | Upgrade
|
Other Unusual Items | 1.14 | - | - | - | - | - | Upgrade
|
Pretax Income | -114.49 | -191.74 | -81.85 | -52.08 | 18.1 | -8.82 | Upgrade
|
Income Tax Expense | 35.29 | 15.3 | 10.69 | 6.28 | -1.71 | -1.59 | Upgrade
|
Net Income | -149.78 | -207.04 | -92.53 | -58.35 | 19.81 | -7.23 | Upgrade
|
Net Income to Common | -149.78 | -207.04 | -92.53 | -58.35 | 19.81 | -7.23 | Upgrade
|
Shares Outstanding (Basic) | 107 | 106 | 105 | 103 | 101 | 97 | Upgrade
|
Shares Outstanding (Diluted) | 107 | 106 | 105 | 103 | 109 | 97 | Upgrade
|
Shares Change (YoY) | 1.49% | 1.65% | 1.19% | -5.00% | 11.97% | 5.89% | Upgrade
|
EPS (Basic) | -1.39 | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 | Upgrade
|
EPS (Diluted) | -1.39 | -1.95 | -0.88 | -0.56 | 0.18 | -0.07 | Upgrade
|
Free Cash Flow | -78.21 | -100.43 | 9.43 | 58.59 | 84.18 | 16.14 | Upgrade
|
Free Cash Flow Per Share | -0.73 | -0.94 | 0.09 | 0.57 | 0.77 | 0.17 | Upgrade
|
Gross Margin | 76.55% | 74.96% | 78.76% | 78.65% | 78.54% | 74.87% | Upgrade
|
Operating Margin | -26.00% | -44.40% | -16.53% | -8.17% | 6.23% | -0.17% | Upgrade
|
Profit Margin | -25.93% | -40.65% | -17.20% | -10.91% | 4.01% | -2.06% | Upgrade
|
Free Cash Flow Margin | -13.54% | -19.72% | 1.75% | 10.95% | 17.03% | 4.59% | Upgrade
|
EBITDA | -140.61 | -216.46 | -79.34 | -34.53 | 38.56 | 6.19 | Upgrade
|
EBITDA Margin | -24.34% | -42.50% | -14.75% | -6.45% | 7.80% | 1.76% | Upgrade
|
D&A For EBITDA | 9.58 | 9.7 | 9.57 | 9.17 | 7.75 | 6.78 | Upgrade
|
EBIT | -150.19 | -226.16 | -88.91 | -43.69 | 30.81 | -0.59 | Upgrade
|
EBIT Margin | -26.00% | -44.40% | -16.53% | -8.17% | 6.23% | -0.17% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.